Cargando…

Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study

INTRODUCTION: Luseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Shinya, Miyake, Teruki, Miyaoka, Hiroaki, Matsuura, Bunzo, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076764/
https://www.ncbi.nlm.nih.gov/pubmed/35426601
http://dx.doi.org/10.1007/s13300-022-01261-9
_version_ 1784701998166179840
author Furukawa, Shinya
Miyake, Teruki
Miyaoka, Hiroaki
Matsuura, Bunzo
Hiasa, Yoichi
author_facet Furukawa, Shinya
Miyake, Teruki
Miyaoka, Hiroaki
Matsuura, Bunzo
Hiasa, Yoichi
author_sort Furukawa, Shinya
collection PubMed
description INTRODUCTION: Luseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study investigated the association between unhealthy eating behavior and the laboratory and physical findings of Japanese patients with type 2 diabetes given luseogliflozin once daily for 24 weeks. METHODS: Twenty-nine patients with type 2 diabetes mellitus were enrolled in a 24-week prospective, open-label, single-arm pilot study. The information regarding unhealthy eating behaviors (eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full) was obtained using self-reported questionnaires. RESULTS: The baseline rate of eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full was 51.7%, 24.1%, 24.1%, 10.3% and 55.2%, respectively. After administration of luseogliflozin, fasting plasma glucose, HbA1c, aspartate aminotransferase (ALT), weight, body mass index, and waist measurement all decreased significantly. High-density lipoprotein cholesterol and hematocrit increased significantly. In the healthy eating behavior group, the improvements of fasting plasma glucose and ALT, but not other variables, were attenuated. HbA1c level was significantly improved in patients with eating fast, while other unhealthy eating behaviors attenuated the effect of luseogliflozin for HbA1c. The effect of leseogliflozin on the relationship between eating behavior and weight reduction was inconsistent after administration luseogliflozin. CONCLUSION: Luseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits.
format Online
Article
Text
id pubmed-9076764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-90767642022-05-08 Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study Furukawa, Shinya Miyake, Teruki Miyaoka, Hiroaki Matsuura, Bunzo Hiasa, Yoichi Diabetes Ther Original Research INTRODUCTION: Luseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unhealthy eating behavior is associated with diabetes, hypertension, and obesity. However, evidence regarding the effect of medications, including SGLT2 inhibitors, on unhealthy eating behavior is limited. This study investigated the association between unhealthy eating behavior and the laboratory and physical findings of Japanese patients with type 2 diabetes given luseogliflozin once daily for 24 weeks. METHODS: Twenty-nine patients with type 2 diabetes mellitus were enrolled in a 24-week prospective, open-label, single-arm pilot study. The information regarding unhealthy eating behaviors (eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full) was obtained using self-reported questionnaires. RESULTS: The baseline rate of eating fast, late dinner, nighttime snack, skipping breakfast, and eating until full was 51.7%, 24.1%, 24.1%, 10.3% and 55.2%, respectively. After administration of luseogliflozin, fasting plasma glucose, HbA1c, aspartate aminotransferase (ALT), weight, body mass index, and waist measurement all decreased significantly. High-density lipoprotein cholesterol and hematocrit increased significantly. In the healthy eating behavior group, the improvements of fasting plasma glucose and ALT, but not other variables, were attenuated. HbA1c level was significantly improved in patients with eating fast, while other unhealthy eating behaviors attenuated the effect of luseogliflozin for HbA1c. The effect of leseogliflozin on the relationship between eating behavior and weight reduction was inconsistent after administration luseogliflozin. CONCLUSION: Luseogliflozin might be more effective for controlling plasma glucose in patients with type 2 diabetes who have a tendency to eat fast, but it might have less effect on those with other unhealthy eating habits. Springer Healthcare 2022-04-15 2022-05 /pmc/articles/PMC9076764/ /pubmed/35426601 http://dx.doi.org/10.1007/s13300-022-01261-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Furukawa, Shinya
Miyake, Teruki
Miyaoka, Hiroaki
Matsuura, Bunzo
Hiasa, Yoichi
Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title_full Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title_fullStr Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title_full_unstemmed Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title_short Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
title_sort observational study on unhealthy eating behavior and the effect of sodium-glucose cotransporter 2 inhibitors: the luseogliflozin ehime diabetes study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076764/
https://www.ncbi.nlm.nih.gov/pubmed/35426601
http://dx.doi.org/10.1007/s13300-022-01261-9
work_keys_str_mv AT furukawashinya observationalstudyonunhealthyeatingbehaviorandtheeffectofsodiumglucosecotransporter2inhibitorstheluseogliflozinehimediabetesstudy
AT miyaketeruki observationalstudyonunhealthyeatingbehaviorandtheeffectofsodiumglucosecotransporter2inhibitorstheluseogliflozinehimediabetesstudy
AT miyaokahiroaki observationalstudyonunhealthyeatingbehaviorandtheeffectofsodiumglucosecotransporter2inhibitorstheluseogliflozinehimediabetesstudy
AT matsuurabunzo observationalstudyonunhealthyeatingbehaviorandtheeffectofsodiumglucosecotransporter2inhibitorstheluseogliflozinehimediabetesstudy
AT hiasayoichi observationalstudyonunhealthyeatingbehaviorandtheeffectofsodiumglucosecotransporter2inhibitorstheluseogliflozinehimediabetesstudy